Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). The company achieved a significant milestone with the accelerated FDA approval of its first therapy for adults with NASH with moderate to advanced liver fibrosis. Madrigal is actively conducting a Phase 3 trial for the treatment of NASH with compensated cirrhosis. The company is dedicated to improving care for patients with NASH/MASH through its ambitious research programs and therapeutic developments.
Liver Disease β’ NASH β’ Metabolic Disease
51 - 200 employees
π Pharmaceuticals
𧬠Biotechnology
βοΈ Healthcare Insurance
π° $259M Post-IPO Equity on 2022-12
March 18
Oversee GCP quality assurance activities for clinical trials at Madrigal, a biopharmaceutical company.
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π‘ Mid-level
π Senior
π§ QA Engineer (Quality Assurance)
π¦ H1B Visa Sponsor
February 22
Lead medical writing efforts for clinical trials at Madrigal focusing on NASH therapies.
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π΄ Lead
βοΈ Content Writer
π¦ H1B Visa Sponsor
February 22
Madrigal Pharmaceuticals seeks a Director of Medical Writing to guide clinical and regulatory documents for NASH treatments.
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π΄ Lead
βοΈ Content Writer
π¦ H1B Visa Sponsor
February 14
Executive Director of Global Market Access at Madrigal overseeing pricing and market access strategies across Europe.
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π΄ Lead
π Director
π¦ H1B Visa Sponsor
February 14
Associate Director of MSAT leads technical strategy for large-scale manufacturing with a cross-functional team at Madrigal.
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π Senior
π Director
π¦ H1B Visa Sponsor
Remote Jobs at Madrigal Pharmaceuticals